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Exogenous misfolded protein 
oligomers can cross the intestinal 
barrier and cause a disease 
phenotype in C. elegans
Michele Perni1,3, Benedetta Mannini1,3, Catherine K. Xu1,3, Janet R. Kumita1, 
Christopher M. Dobson1, Fabrizio Chiti2* & Michele Vendruscolo1*
Misfolded protein oligomers are increasingly recognized as highly cytotoxic agents in a wide range of 
human disorders associated with protein aggregation. In this study, we assessed the possible uptake 
and resulting toxic effects of model protein oligomers administered to C. elegans through the culture 
medium. We used an automated machine-vision, high-throughput screening procedure to monitor the 
phenotypic changes in the worms, in combination with confocal microscopy to monitor the diffusion 
of the oligomers, and oxidative stress assays to detect their toxic effects. Our results suggest that the 
oligomers can diffuse from the intestinal lumen to other tissues, resulting in a disease phenotype. We 
also observed that pre-incubation of the oligomers with a molecular chaperone (αB-crystallin) or a 
small molecule inhibitor of protein aggregation (squalamine), reduced the oligomer absorption. These 
results indicate that exogenous misfolded protein oligomers can be taken up by the worms from their 
environment and spread across tissues, giving rise to pathological effects in regions distant from their 
place of absorbance.
Numerous human disorders, including Alzheimer’s and Parkinson’s diseases are associated with the aberrant 
aggregation of  proteins1–5. In most cases, these disorders are still incurable, in part because of the incomplete 
understanding of the mechanism of formation and spreading of protein aggregates. Among the wide vari-
ety of misfolded and aggregated protein species, small oligomeric forms, are increasingly recognized to be 
highly  cytotoxic6–14. These oligomers are produced during the aggregation process through a variety of complex 
 processes15,16, and it has been shown that they undergo a conversion from disordered to more ordered forms 
and subsequently mature into amyloid  fibrils16.
In particular, different types of α-synuclein oligomers have been reported under different  conditions17–22, 
including two stable forms, denoted type A and type B, being non-toxic and toxic,  respectively23–26. Type A oli-
gomers have no detectable β-sheet structure, while type B oligomers have a level of such structure intermediate 
between that of monomers and  fibrils23–26. It has been shown in particular that the toxic type B oligomers are 
able to anchor, through their flexible N-termini, to the membrane, which is then penetrated and destabilized 
through their structured β-sheet  core25. Similarly, the N-terminal domain of HypF (HypF-N) from E. coli has 
also been shown to form model toxic and non-toxic oligomeric  species27–29.
We describe here an investigation of the mechanisms of toxicity associated with oligomeric species from 
α-synuclein and HypF-N, using the nematode worm C. elegans. Our choice of C. elegans was based on its proven 
versatility for whole-organism high-throughput  genetic30–34 and  drug35–37 screening. The worms are small (1 mm 
in length), transparent, and easy to  manipulate38. In addition, their cellular complexity is comparable to that 
of higher  organisms34,38 and their short life-span of about 3 weeks facilitates the rapid study of a wide range of 
biological  phenotypes38. Indeed, C. elegans has been employed as a model organism for studying the phenotypic 
effects of protein  aggregation39–42, for the identification of age-related genes and genetic pathways, and for screen-
ing protein aggregation  inhibitors40,43,44.
In this work, we established a protocol to deliver the oligomers to C. elegans, investigated how the oligomers 
were adsorbed and then monitored the resulting effects of the oligomers on the overall fitness of the worms.
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Results
Delivery of protein oligomers to C. elegans. The metastable and heterogeneous nature of misfolded 
protein oligomers makes it challenging to study their structures and properties and to understand at the molecu-
lar level the ways in which they interact with the components of biological  systems2,14,16. In order to address such 
questions, we started our investigations by considering model oligomers formed by HypF-N. HypF-N forms 
spherical oligomers and amyloid-like fibrils in vitro, under conditions that destabilize its native  structure45–48. 
Furthermore, when added to the extracellular medium of cultured cells or injected into rat brains, the oligom-
ers induce similar biochemical, electrophysiological, and cell biological responses to oligomers associated with 
neurodegenerative  diseases6,28,29,49–54. HypF-N oligomers represent powerful research tools, as HypF-N can be 
converted into two different types of oligomers, denoted type A and type B, where the former is toxic and the 
latter is  not27–29. Both types are sufficiently stable to allow detailed structural and biological studies to be carried 
 out27–29,51,53–55. These two oligomeric species have similar sizes and morphologies, and both have a high content 
of β-sheet structure and the ability to bind the amyloid-specific dye thioflavin T (ThT) to a moderate but signifi-
cant  extent27,55.
We added toxic type A and non-toxic type B HypF-N oligomers, prepared as described previously (see Meth-
ods), to the worm growth media at concentrations of 6–48 μM, so that the worms were continuously exposed 
to the oligomers (Fig. 1). We found the optimal parameters for these experiments to be a density of about 1.2 
worms μl−1, a duration of incubation of 6–12 h, a volume of media of 750 μl in a 1.5 ml tube to avoid suffoca-
tion of the worms and a degree of agitation of 60 rounds per minute (rpm) at 20 °C. We used Eppendorf tubes 
rather than solid media or multi-well plates in order to minimize the stress to the animals while at the same time 
Figure 1.  Schematic description of the protocol to probe the effects of exposure of C. elegans to misfolded 
protein oligomers. (A) Oligomers were formed as described  previously23,24,27. (B) Worms were incubated at day 
0 (D0) with the different oligomeric species for 6–12 h. (C) Diffusion of labeled oligomers through the intestinal 
barrier was monitored through confocal microscopy. (D) High-throughput strategies were used to screen for 
worm fitness after exposure.
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increasing their exposure to the oligomers. We also tested a variety of different media compatible with the growth 
of C. elegans, including Hepes, phosphate-buffered saline (PBS), plain water and M9 buffer at physiological pH 
7.4, and a range of different ages of the worms for oligomer administration and screened their fitness with a 
completely automatically  procedure56.
To optimize the exposure of the worms to the oligomers, we found advantageous to perform the incubation 
in solution, rather than on agar plates where the oligomers were more easily degraded or avoided by the animals. 
We screened the behavior of the worms by means of a recently developed automated high throughput  platform56, 
and examined about 600 worms for each condition used in this study.
Type A and type B HypF-N oligomers exhibit different toxicities in C. elegans. Type A HypF-N 
oligomers were found to cause significant changes to the motility of the worms at all concentrations tested, and 
also to show a marked dose dependence of the effects (Fig. 2A). By contrast, type B oligomers and native proteins 
were found to have no detectable effects at any of the concentrations studied in this work (6–48 μM and 48 μM 
respectively) (Fig. 2A). Moreover, we observed that type A oligomers affected significantly other characteristics 
of the behavior of the worms, including swimming speed and rate of paralysis, while the type B and monomeric 
native HypF-N showed only marginal effects on any of these parameters. The data are summarized (Fig. 2B) by 
multi-parametric fingerprinting maps, which identify multiple metrics in parallel and define a total fitness score.
We found that the effects of the oligomers were most evident following their early administration at day 0 (D0) 
of adulthood with 750 μl of M9 buffer at pH 7.4 (Fig. 2A, the motility is normalized to the value of the vehicle). 
Administration at day 4 (D4) of adulthood showed less pronounced effects, which were only evident for type A 
HypF-N oligomers and only at the highest concentrations tested (> 24 μM) (Figure S1).
We also measured production of reactive oxidative species (ROS) using a luminometer (Methods). After 
incubation times of up to 6 h, a significant production of ROS and a clear dose dependence was observed with 
type A oligomers, whereas the effects of type B oligomers and native HypF-N were found to be negligible and 
non-significant (Fig. 2C).
Figure 2.  Effects of early exposure to HypF-N oligomers on worm fitness. (A) Type A (red) and type B (blue) 
oligomers of HypF-N27, at 6, 12, 24, 48 μM and native HypF-N at 48 μM (green) were administered to C. elegans 
at day 0 (D0). 600 animals were analyzed in each experiment, and a representative of three replicas, which 
showed similar results, is shown. Statistical tests (Student’s t test) were carried out using Graph-pad prism. All 
tests have been two tailed unless stated otherwise. Error bars indicate the standard error of the mean (SEM). The 
double (**), triple (***) and quadruple (****) asterisks indicate P ≤ 0.01, 0.001 and 0.0001, respectively, relative 
to unexposed worms. (B) High resolution phenotypical fingerprinting carried out using WF-NTP. Multiple 
fitness readouts (speed, bends per minute, bend magnitude, distance per bend and live ratio) are reported. Up 
to 1200 animals per condition were analyzed. Thick colored lines indicate the mean and SEM values. (C) ROS 
production in worms exposed at D0 with type A (red) and type B (blue) oligomers of HypF-N27, at 6, 12, 24, 
48 μM and native HypF-N at 48 μM (green) Bars indicate the means and SEM values.
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Toxic HypF-N oligomers are adsorbed from the guts in C. elegans. We next sought to elucidate 
the mechanism by which toxic type A HypF-N oligomers are able to exert their detrimental effects on C. elegans. 
For this purpose, we screened HypF-N oligomers fluorescently labeled with the dye fluorescein-5-isothiocy-
anate (5-FITC), and acquired confocal microscopy images to evaluate their localization within the worm bod-
ies (Figs. 3A, 4). Measurement of the intensity of the fluorescence signals showed that both type A and type B 
oligomers were rapidly ingested by the worms, and in both cases the oligomers were located in the intestinal 
lumen after 2 h of incubation. After longer incubation times (from 6 to 12 h), however, substantial differences 
were observed between these two types of oligomers. These results suggest that type A oligomers are able to pass 
through the intestinal lumen and to diffuse into the internal tissues of the worms. By contrast, type B oligomers 
appear to remain in the intestinal lumen even after 12 h of incubation (Fig. 3A) where they are likely to be slowly 
degraded.
Quantification of the fluorescence intensities arising from the labeled oligomers was then carried out to 
compare their levels in the intestinal lumen and in nearby tissues (Fig. 3B) In the case of type B oligomers, we 
found that after 12 h of incubation the majority of the fluorescently tagged oligomers (78%) were localized within 
the intestinal lumen of the animals. In the case of type A oligomers, we observed that the vast majority of the 
signal (67%) came from the adjacent tissues with only 33% in the intestinal region (Fig. 3B). The phenotypic 
Figure 3.  Oligomer uptake from the intestinal lumen to the internal tissues of the worms. (A) Representative 
images of oligomer localisation obtained by confocal microscopy. Horizontal bars in the images indicate 100 μm. 
(B) Quantification of uptake of the oligomers from the intestinal lumen (inside) to the internal tissues (outside) 
of the worms. Worms were exposed to 12 µM of type A, or type B oligomers or with type of A oligomers with 
αB-crystallin (αBc) at a 5:1 HypF-N:αB-crystallin molar ratio (Type A + αBc) at D0. HypF-N was labeled with 
5-FITC or unlabeled. All oligomers were incubated with 300 wild-type worms over a period of 12 h, after which 
confocal microscopy images were acquired. Bars indicate mean and SEM values. (C) Analysis of the motility of 
worms exposed at day 0 (D0) to 48 µM type B (blue), type A (red), type A oligomers with 9.6 μM αB-crystallin 
(pink) or left unexposed (“vehicle”, grey) and treated with αB-crystallin only (“vehicle + αBc”, yellow) and 
analyzed after 6 h of incubation. Bars indicate mean and SEM values. One representative of three experiments, 
all of which showed similar results, is shown. Statistical tests (Student’s t test) were carried out using Graph-pad 
prism. The triple (***) asterisks indicate P ≤ 0.001, relative to worms exposed to type A oligomers.
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analysis indicates that the motility of the worms was reduced only when the animals were exposed to type A 
oligomers (Fig. 2A,B).
These results are consistent with the possibility that the type A oligomers could penetrate the intestinal cells 
of the worms, and that this causes widespread toxicity. Type B oligomers, by contrast, appear unable to disrupt 
to any significant degree the integrity of the cells of the intestine, in which they remain confined and where 
eventually they are degraded, an effect likely to be a result of continuous exposure to the highly acidic pH of the 
intestinal  lumen57. The different ability of the two types of oligomers to interact with cell membranes has previ-
ously been shown to be responsible for differential toxic effects in cultured neuroblastoma cells where only type 
A oligomers were found to disrupt cellular  membranes27,29. The set of confocal microscopy images reported here 
is consistent with the hypothesis that an important mechanism of action of oligomeric aggregates associated with 
perturbed motility involves the impairment of the integrity of cellular  membranes25.
We then carried out experiments to investigate if the HypF-N type A oligomers localize in the body wall 
muscle cells of the worms. In order to investigate this point, we used worms that express the yellow fluorescent 
protein (YFP) in the body wall muscle  cells46 and administered to them type A oligomers tagged with 5-FITC 
(Fig. 4). Despite the relatively low intensity of the 5-FITC signal, there was a clear colocalization between the 
labelled oligomers and the YFP, indicating that the oligomers reach the muscle cells from the gut lumen. Interest-
ingly, we could also observe an increased fluorescent signal arising from the muscle tissue when the worms were 
administered fluorescent type A oligomers, suggesting that the muscle cells also change their levels of protein 
expression (Fig. 4). These results suggest accumulation of the toxic species in the body wall muscle cells, although 
the oligomers seem to diffuse also to other tissues within the body of the worms (Figure S2).
αB-crystallin reduces the toxicity of HypF-N oligomers. In order to explore further the link between 
the location of the oligomers within the worms and their toxicity, and to assess the degree by which such toxicity 
arises from the ability of these species to cross the intestinal cell walls, we also pre-incubated type A HypF-N 
oligomers with αB-crystallin at a molar ratio of 5:1 for 1 h before administering them to the worms and incubat-
ing for 12 h (Fig. 3A–C). αB-crystallin is a molecular chaperone that has been shown to be able to reduce the 
toxicity of HypF-N type A oligomers in cell cultures by promoting their assembly into species that cannot readily 
Figure 4.  Confocal microscopy analysis of HypF-N type A oligomer co-localisation with muscle cells. Analysis 
by confocal microscopy of worms expressing YFP in the body wall muscle  cells46 left untreated (top panels) or 
exposed to 12 µM of type A oligomers (bottom panels). 300 wild-type worms were exposed over a period of 
16 h, after which confocal microscopy images were acquired; horizontal bars indicate 80 µm.
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pass through the cell  wall52,63. Following exposure of the worms with type A oligomers pre-incubated with this 
molecular chaperone, the motility of the worms was substantially higher than that of the worms exposed to type 
A oligomers in the absence of αB-crystallin. Indeed, it was found to be similar to that of the worms exposed to 
the medium alone or to type B oligomers (Fig. 3C). In addition, the fluorescence data showed that the type A 
oligomers treated with αB-crystallin remained overwhelmingly within the intestinal lumen (Fig. 3A), providing 
further evidence of the link between the toxicity of the oligomers and their ability to diffuse through the intes-
tinal cell walls.
α-Synuclein oligomers reduce worm motility and increase ROS production. In order to study 
directly α-synuclein oligomers, we exposed the worms to toxic type B oligomers. We previously reported that 
the exposure to such oligomers was highly toxic to human SH-SY5Y neuroblastoma cells and primary neurons, 
as observed from an increase in ROS,  Ca2+ uptake and calcein release through disruption of cellular membranes 
and a decrease in mitochondrial  activity23,25,58,59. In those studies, we observed a decrease in toxicity, not just at 
lower α-synuclein concentrations, but also at higher concentrations, an effect that can be attributed to the further 
aggregation (agglutination) of the oligomers into large  assemblies60, a phenomenon typical of hydrophobic col-
loids, such as our oligomers, in water solutions. In the present work, α-synuclein oligomers were administered 
to the worms at the D0 stage and were observed to have effects similar to those of the type A HypF-N oligomers, 
with the maximum effect on motility (Fig. 5A,B) and ROS (Fig. 5C) production observed at a concentration of 
5 μM (monomer equivalents). The dose dependence was similar to that observed with the neuroblastoma cells, 
except that the concentration of maximum toxicity in the worms was some ten times higher than that in the 
cells, suggesting that the effective concentration that was established within the worm bodies was lower than in 
the case of the cell cultures. These results indicate that the toxic effects observed in C. elegans for the HypF-N 
oligomers are also found for the disease-related oligomeric species of α-synuclein, that are associated with the 
pathogenesis of PD.
Treatment with squalamine reduces the toxicity of type B α-synuclein oligomers. In a series 
of additional experiments, the toxic type B oligomers of α-synuclein were preincubated with the aminosterol 
squalamine (Fig. 5D,E), which was shown to have a substantial protective effect against the toxicity of these 
oligomers in neuronal cells and when formed following overexpression in C. elegans56. A similar protective effect 
against the toxicity of the same oligomers in neuronal cells was also found for the structurally similar molecule 
trodusquemine, which has a spermine moiety rather than a spermidine  group61. The results showed that this 
procedure reduced the deleterious effects of the addition of pre-formed α-synuclein oligomers (Fig. 5D), and 
confocal microscopy confirmed that the administration of α-synuclein oligomers incubated with squalamine 
greatly reduced their capacity to permeate the gut walls (Fig. 5E).
Discussion
We have described the toxic effects of protein oligomers administered exogenously in the model organism C. 
elegans. We first studied oligomers of the model protein HypF-N, from which stable oligomers that are both 
toxic (type A) and non-toxic (type B) to neuronal cells in culture can be  generated27–29,51,53–55 by adding them to 
the worm culture medium. We then evaluated the effects on the worms exposed to these species by means of an 
automated tracking  platform56, which enabled high-throughput and highly sensitive measurements of the effects 
on the fitness of the animals to be  made56,62–64.
We observed a high level of toxicity in the worms incubated with type A HypF-N oligomers, with negligible 
effects observed following incubation with the type B or the native HypF-N protein. We also measured a higher 
oxidative stress in the worms exposed to type A oligomers relative to those exposed to type B oligomers or native 
proteins, where the observed effects were very small. We further observed that only type A oligomers were capa-
ble of passing through the intestinal membrane and diffusing into nearby tissues. This result shows the strong 
link between the properties of the intestinal cells of the worm and their health and  lifespan65,66, pointing at the 
importance of this entry route for oligomeric species in this system. Unlike type A oligomers, type B oligomers 
were found to be unable to penetrate the membranes of the cells of the intestinal wall and to cause significant 
detrimental effects. This difference in behavior of the two types of oligomers observed in this animal model 
system correlates with that observed previously in cell  cultures27–29,51,53–55 supporting the conclusion that the 
interaction with cell membranes plays a central role in determining the toxicity of the oligomers. Indeed, it was 
previously found that toxicity of misfolded protein oligomers to cell cultures correlates with both exposure of 
hydrophobic groups and small size of the oligomers, which favors their rapid diffusion through the lipid bilayer of 
cell  membranes27–29,51,53–55,67, a finding that is confirmed in the present report showing an ability of the oligomers 
to diffuse through such the membranes. This finding was reinforced further by incubating the HypF-N oligom-
ers with the molecular chaperone αB-crystallin, which has previously been shown to be protective against the 
toxicity of the type A oligomers in a cellular  system50. In the presence of αB-crystallin a marked increase in the 
fitness of the worms was observed, relative to that in the absence of the molecular chaperone.
We then extended these results to a type of α-synuclein oligomers that have been shown previously to be 
toxic to cultured  cells23–25,58,59. We observed dose-dependent toxic effects similar to those found in cultured 
neuroblastoma cells and primary neurons. Furthermore, incubation with small therapeutic molecules, such as 
the aminosterol squalamine, found previously to be protective in cell models and in transgenic PD strains of C. 
elegans by binding to the cell membrane and displacing oligomeric α-synuclein56, suppresses dramatically the 
oligomeric toxicity in this system. Given that the populations of oligomers produced during aggregation reactions 
is highly heterogeneous in conformational and physico-chemical  properties68, the results that we have reported 
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for HypF-N and α-synuclein oligomers provide further insight into the relationship between these properties 
and  cytotoxicity25,53,69,70.
In a broader context, it has been suggested that Parkinson’s disease may in certain cases originate in the gastro-
intestinal tract before progressing to the  brain71–73. Accumulation of α-synuclein has been observed in the enteric 
nervous system (ENS), which spans the entire gastrointestinal tract, as well as in the stomach, duodenum and 
colon of PD patients and healthy  individuals74–76. In this mechanism of disease, pathological forms of α-synuclein 
may ascend ENS-innervating vagal fibers to the nodose ganglion and brainstem  nuclei71. Indeed, it has recently 
been reported that inoculation of preformed fibrils of α-synuclein in the duodenal intestinal lining of ageing 
Figure 5.  Effects of the exposure to type B α-synuclein oligomers on the worm fitness. (A) Worms were 
exposed at day 0 (D0) of adulthood to type B α-synuclein (αS)  oligomers23,24 at 1, 2.5, 5, 7.5, 10 and 20 μM 
(monomer equivalents), the motility is normalized to the value of the vehicle. 600 worms were analyzed 
after 6 h exposure per condition. Bars indicate mean and SEM values. One experiment representative of 
three, which showed similar results, is shown. Statistical tests (Student’s t test) were carried out using Graph-
pad prism. The double (**), triple (***) and quadruple (****) asterisks indicate P ≤ 0.01, 0.001 and 0.0001, 
respectively, relative to unexposed worms. (B) High resolution phenotypical fingerprinting carried out using 
the wide field of view nematode tracking platform (WF-NTP, colors as in (A). Multiple fitness readouts (speed, 
bends per minute, bend magnitude, distance per bend and live ratio) are reported. Up to 1200 animals per 
condition were analyzed. Thick coloured lines indicate mean and SEM values. (C) ROS production in worms 
exposed at day 0 (D0) to α-synuclein oligomers at 1, 2.5, 5, 7.5, 10 and 20 μM (monomer equivalents). Bars 
indicate the means and SEM values. (D) Quantification of the worm behavior after exposure at D0 to 2.5 µM 
α-synuclein oligomers without or with 10 µM squalamine. Bars indicate mean and SEM values. Approximately 
600 worms were analysed after incubation for 6 h. (E) Confocal microscopy images of worms exposed at D0 
with 2.5 μM α-synuclein oligomers labeled with 5-FITC (right) or without (left) 12.5 µM squalamine at a 
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mice can lead to brain  pathology77,78. It has also been suggested that amyloid aggregates from the gut flora in 
mice could cross the gut barrier and trigger α-synuclein in the  ENS79,80. Although the mechanism of formation 
of α-synuclein aggregates in the human ENS has yet to be fully clarified, our results provide additional insight 
into the hypothesis that α-synuclein aggregates originating from the gut can spread to other regions of the body.
Conclusions
We have shown that misfolded protein oligomers have different abilities to gain access from the gut lumen to spe-
cific types of tissues in C. elegans. This differential uptake can be linked to the ability of certain types of exogenous 
oligomers of environmental origin to cross the intestinal barrier and to diffuse through the internal tissues of the 
worms. As these processes can be linked to the ability of the most cytotoxic oligomers to cross cell membranes, 
these results provide a glimpse on the importance of aggregate spreading in protein misfolding diseases.
Materials and methods
Media. Standard conditions were used for the propagation of C. elegans81–83. Briefly, the animals were syn-
chronized by hypochlorite bleaching, hatched overnight in M9 buffer (3 g  l−1  KH2PO4, 6 g  l−1  Na2HPO4, 5 g  l−1 
NaCl, 1 µM  MgSO4), and subsequently cultured at 20 °C on nematode growth medium plates (NGM, 1 mM 
 CaCl2, 1 mM  MgSO4, 5 µg  ml−1 cholesterol, 250 µM  KH2PO4, pH 6.0, 17 g  l−1 Agar, 3 g  l−1 NaCl, 7.5 g  l−1 casein), 
seeded with the E. coli strain OP50. Saturated cultures of OP50 were grown by inoculating 50 ml of LB medium 
(10 g  l−1 tryptone, 10 g  l−1 NaCl, 5 g  l−1 yeast extract) with OP50 and incubating the culture for 16 h at 37 °C. 
NGM plates were seeded with bacteria by adding 350 µl of saturated OP50 to each plate and leaving the plates at 
20 °C for 2–3 days. On day 3 after synchronization, the animals were placed on NGM plates containing 5-fluoro-
2′deoxy-uridine (FUDR) (75 µM, unless stated otherwise) to inhibit the growth of offspring.
Strains of C. elegans. We used the C. elegans Var Bristol (known as N2), which has a generation time of 
about 3 days and a brood size of about 350  worms38. We also used worms that express the yellow fluorescent 
protein (YFP) in the body wall muscle cells, known as  OW45046.
Preparation of HypF-N oligomers. HypF-N oligomers were obtained as described  previously27. Briefly, 
type A and type B monomers were incubated at 48 μM for 4 h at 25 °C under two conditions: (1) 50 mM acetate 
buffer, 12% (v/v) trifluoroethanol (TFE), 2  mM dithiothreitol (DTT), pH 5.5 (condition A) and (2) 20  mM 
trifluoroacetic acid (TFA), 330 mM NaCl, pH 1.7 (condition B). The oligomers were centrifuged at 16,100 g for 
10 min, dried under  N2 and resuspended in M9 buffer at the desired concentration. Type A  oligomers50 were 
resuspended also in M9 buffer at a concentration of 48 µM (monomer equivalents) with αB-crystallin (Abcam 
PLC, Cambridge, UK) at the HypF-N-to-chaperone molar ratio of 5:1 for 1 h at 37 °C while shaking. As a control, 
samples containing the same concentration of αB-crystallin was incubated under the same conditions, in the 
absence of the oligomers, and then administered to the worms.
Purification of α-synuclein. α-Synuclein protein expression, purification and oligomer formation were 
carried out as described  previously24. Briefly, α-synuclein was purified from Escherichia coli BL21 cells over-
expressing α-synuclein, which were lysed by sonication. Heat-sensitive proteins were precipitated out of the 
lysate supernatant by boiling. Following centrifugation, streptomycin sulphate was added to the supernatant 
and centrifuged again. α-Synuclein was precipitated out of the supernatant by addition of ammonium sulphate 
(361 mg  ml−1) and stirring at 4 °C for 30 min. The precipitated α-synuclein was resuspended 25 mM Tris buffer, 
pH 7.4, 20 °C and loaded onto a HiLoad 26/10 Q Sepharose high performance column (GE Healthcare Ltd., 
Little Chalfont, UK), and eluted at ~ 350 mM NaCl, 20 °C with a salt gradient from 0 to 1.5 M NaCl. Selected 
fractions were subsequently loaded onto a Superdex 75 26/60 (GE Healthcare Ltd.) at 20 °C and eluted in PBS, 
pH 7.4, 20 °C. Protein concentration was determined by absorbance at 275 nm, using an extinction coefficient 
of 5600  M−1  cm−1.
Preparation of α-synuclein oligomers. Samples enriched in oligomeric α-synuclein species were pre-
pared as previously  described24. Briefly, monomeric α-synuclein was lyophilized in Milli-Q water and subse-
quently resuspended in PBS, pH 7.4, 20 °C, to give a final concentration of ca. 800 µM (12 mg  ml−1). The result-
ing solution was passed through a 0.22 µm cut-off filter before incubation at 37 °C for 20–24 h under quiescent 
conditions. Small amounts of fibrillar species formed during this time were removed by ultracentrifugation for 
1 h at 90,000 rpm (using a TLA-120.2 Beckman rotor, 288,000 g). The excess monomeric protein and some small 
oligomers were then removed by multiple filtration steps using 100-kDa cut-off membranes. The final concen-
tration of oligomers was estimated on the basis on the absorbance at 275 nm using a molar extinction coefficient 
of 5600  M−1  cm−1.
Delivery of the oligomers. About 600 worms were incubated in M9 buffer with appropriate concentra-
tions of protein oligomers or native proteins in a final volume of 750 μl in 1.5 ml low binding Eppendorf tubes up 
to 6–12 h under mild shaking (60 rpm) in horizontal position at room temperature. After incubation, the worms 
were plated on agar and the parameters defining their fitness were analyzed in an automated  manner56,84. Motil-
ity procedures were carried out after 6 h incubation, and imaging was performed after 24 h after incubation. All 
experiments were carried out in triplicate. One experiment in each case that is representative of the three inde-
pendent measurements is shown in the figures. We note that the present protocol differs from a previously pro-
posed  one85, as in our case we do not feed the worms with E. coli engineered to express the oligomerizing protein.
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Image analysis. Image analysis was carried out as previously  described27. Briefly, we used a custom software 
written in Python (Python Software Foundation), which is part of the WF-NTP  platform56,84. This code initially 
detects and subtracts the background, consisting of non-moving objects such as small particles and shadows 
from the agar plate. After this operation, the remaining labeled regions are identified as individual worms and 
the positions of said regions are then stored for each frame. The eccentricity of each tracked worm, a measure of 
the ratio of the major and minor ellipse axes, can then be used to estimate worm bending as a function of time. 
Through this method, individual worms were tracked over time, and plots of their movement extracted to give 
visual information about their mobility levels.
Automated motility assay on agar plates. All C. elegans populations were cultured at 20 °C and devel-
opmentally synchronized from a 4 h egg-lay. At 64–72 h post egg-lay (time zero) individuals were transferred to 
FUDR plates. At specific ages, the animals were washed off the plates with M9 buffer and incubated with specific 
oligomers. After 12 h of incubation, the worms were spread over an OP-50 un-seeded 9 cm plate, after which 
their movements were recorded at 20 fps using a novel microscopic setup for 30 s or 1  min56. Up to 600 animals 
in triplicate were counted in each experiment unless stated otherwise. One experiment that is representative of 
the three measured is shown in each case. Videos were analyzed using a custom-made tracking  code56,84. All 
statistical tests (Student’s t test) were carried out using Graph-pad prism. All tests have been two tailed unless 
stated otherwise.
Protein labelling. Monomeric HypF-N was buffer exchanged in phosphate buffered saline (PBS) solution at 
pH 7.4, 4 °C, or oligomeric α-synuclein prepared in PBS, and then labelled with the probe 5-FITC using the Ana-
Tag 5-FITC Microscale Protein Labeling Kit (AnaSpec, San Jose, CA, USA). The protein:5-FITC molar ratio was 
2:1, to reduce the possible impact of the probe on the aggregation process. The degree of labelling was evaluated 
by measuring the absorbance of the protein at 280 nm and of the dye at 494 nm, according to the manufacturer’s 
protocol. The labelled proteins were then converted into their corresponding oligomers.
Confocal microscopy imaging. The fluorescence of 5-FITC-tagged HypF-N and α-synuclein was quanti-
fied using a Leica SP8 confocal microscopy system (Leica Microsystems, Mannheim, Germany) at a nominal 
magnification of 10X or 20X; for each picture we acquired 20 stacks of 0.7 μm/each. Measurements of fluo-
rescence intensity were performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). 
At least 30 animals were examined per condition, unless stated otherwise. All experiments were carried out in 
triplicate and the data from one representative experiment are shown in the figure. The Student’s t test was used 
to calculate p values, and all tests were two-tailed unpaired unless otherwise stated.
Colocalization studies. The internal localisation of 5-FITC-tagged HypF-N type A oligomers was followed 
using a Leica SP8 confocal microscopy system (Leica Microsystems, Mannheim, Germany) at a nominal magni-
fication of 10X; for each picture we acquired 20 stacks of 0.7 μm/each using both the 5-FITC and YFP channels. 
The resulting images were then merged using the ImageJ software (National Institutes of Health, Bethesda, MD, 
USA). At least 30 animals were examined per condition. All experiments were carried out in triplicate and the 
data from one representative experiment are shown in the figure.
ROS production and measurement. A ROS-Glo  H2O2 cell kit assay was used (Promega, Fitchburg, 
Wisconsin, USA). The ROS-Glo  H2O2 Assay is a bioluminescent assay that measures the level of  H2O2, a reactive 
oxygen species (ROS), directly in cell culture or tissue or in defined enzyme reactions. A derivatized luciferin 
substrate is incubated with sample and reacts directly with  H2O2 to generate a luciferin precursor. We adapted 
the protocol for C. elegans studies as follows: 500 AD worms and 500 control worms exposed to different oli-
gomers, respectively, were collected at the D0 of adulthood and incubated for 6 h with a ROS Substrate Solution 
(Promega, Fitchburg, Wisconsin, USA), with mild shaking to avoid worms sedimentation, after which they were 
incubated for 20 min with the detection solution and the luminescence was then measured with a luminescence 
GloMax Explorer System (Promega, Fitchburg, Wisconsin, USA).
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